Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study

REPOSIT study group

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

10 Citaten (Scopus)

Vingerafdruk

Duik in de onderzoeksthema's van 'Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study'. Samen vormen ze een unieke vingerafdruk.

Sorteer per
Gewicht
Alfabetische volgorde

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study

Vingerafdruk

Medicijnen en Levenswetenschappen